DNLI241220C17500
- 5.50
- 0.000.00%
Denali Therapeutics Newsroom
Denali Therapeutics Upgraded to Buy From Hold at Stifel
Stifel Upgrades Denali Therapeutics(DNLI.US) to Buy Rating, Raises Target Price to $37
Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target
Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
Express News | Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of Lrrk2 Inhibitor, Biib122, in Lrrk2-Associated Parkinson’s Disease
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease
Denali Therapeutics Management to Meet With B. Riley
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $38
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $33
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
Denali Therapeutics (DNLI) Receives a Hold From Stifel Nicolaus
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $41
Express News | Denali Therapeutics Inc : Wedbush Raises Target Price to $33 From $30
HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $90
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating